GlaxoSmithKline Pharmaceuticals has decided to transfer its rights in relation to the Iodex and Ostocalcium brands to GlaxoSmithKline Asia, for an aggregate consideration of Rs 1649 crore. The transaction is expected to be completed before the end of the year, subject to shareholder approval and the customary closing conditions, including relevant regulatory approvals.
GlaxoSmithKline Pharmaceuticals is an Indian subsidiary of GlaxoSmithKline plc. The company business has a broad portfolio of innovative and established medicines, with leadership positions in respiratory and HIV.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.75 |
| Dr. Reddys Lab | 1233.95 |
| Cipla | 1231.60 |
| Zydus Lifesciences | 938.70 |
| Lupin | 2328.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: